Publications

Leisha Emens

Emens LA. Immunotherapy in Triple-Negative Breast Cancer. Cancer J. 2021 Jan-Feb 01;27(1):59-66. doi: 10.1097/PPO.0000000000000497. PubMed PMID: 33475294.
Mi H, Gong C, Sulam J, Fertig EJ, Szalay AS, Jaffee EM, Stearns V, Emens LA, Cimino-Mathews AM, Popel AS. Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast Cancer. Front Physiol. 2020;11583333. doi: 10.3389/fphys.2020.583333. PubMed PMID: 33192595; PMCID: PMC7604437.
Emens LA, Esteva FJ, Beresford M, Saura C, De Laurentiis M, Kim SB, Im SA, Wang Y, Salgado R, Mani A, Shah J, Lambertini C, Liu H, de Haas SL, Patre M, Loi S. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. Lancet Oncol. 2020 Oct;21(10):1283-1295. doi: 10.1016/S1470-2045(20)30465-4. PubMed PMID: 33002436.
Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019 Aug;154(2):314-322. doi: 10.1016/j.ygyno.2019.05.021. PubMed PMID: 31204078.
Schmid P, Chui SY, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply. N Engl J Med. 2019 Mar 7;380(10):987-988. doi: 10.1056/NEJMc1900150. PubMed PMID: 30855757.
Emens LA, Davis SL, Oliver SCN, Lieu CH, Reddy A, Solomon S, He L, Morley R, Fassò M, Pirzkall A, Patel H, O'Hear C, Ferrara D. Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal Venulitis. JAMA Ophthalmol. 2019 Jan 1;137(1):96-100. doi: 10.1001/jamaophthalmol.2018.5191. PubMed PMID: 30383154; PMCID: PMC6439799.
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R, Cassier PA, Delord JP, Gordon MS, ElGabry E, Chang CW, Sarkar I, Grossman W, O'Hear C, Fassò M, Molinero L, Schmid P. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study. JAMA Oncol. 2019 Jan 1;5(1):74-82. doi: 10.1001/jamaoncol.2018.4224. PubMed PMID: 30242306; PMCID: PMC6439773.
Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018 Jun 18;6(1):57. doi: 10.1186/s40425-018-0360-8. PubMed PMID: 29914571; PMCID: PMC6006764.
Litvak A, Batukbhai B, Russell SD, Tsai HL, Rosner GL, Jeter SC, Armstrong D, Emens LA, Fetting J, Wolff AC, Silhy R, Stearns V, Connolly RM. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer. 2018 May 1;124(9):1904-1911. doi: 10.1002/cncr.31260. PubMed PMID: 29381193; PMCID: PMC5910274.
Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV, Emens LA. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Hum Gene Ther. 2018 May;29(5):614-625. doi: 10.1089/hum.2017.080. PubMed PMID: 29334771; PMCID: PMC5930796.
Ojalvo LS, Thompson ED, Wang TL, Meeker AK, Shih IM, Fader AN, Cimino-Mathews A, Emens LA. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer. Hum Pathol. 2018 Apr;74135-147. doi: 10.1016/j.humpath.2017.12.010. PubMed PMID: 29288043.
Emens LA, Bruno R, Rubin EH, Jaffee EM, McKee AE. Report on the Third FDA-AACR Oncology Dose-Finding Workshop. Cancer Immunol Res. 2017 Dec;5(12):1058-1061. doi: 10.1158/2326-6066.CIR-17-0590. PubMed PMID: 29196440.
Emens LA. Breast Cancer Immunotherapy: Facts and Hopes. Clin Cancer Res. 2018 Feb 1;24(3):511-520. doi: 10.1158/1078-0432.CCR-16-3001. PubMed PMID: 28801472; PMCID: PMC5796849.
Thompson ED, Taube JM, Asch-Kendrick RJ, Ogurtsova A, Xu H, Sharma R, Meeker A, Argani P, Emens LA, Cimino-Mathews A. PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast. Mod Pathol. 2017 Nov;30(11):1551-1560. doi: 10.1038/modpathol.2017.79. PubMed PMID: 28731046.
Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer. 2017 Aug;81116-129. doi: 10.1016/j.ejca.2017.01.035. PubMed PMID: 28623775.
Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr, Emens LA. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunol Res. 2017 Jun;5(6):468-479. doi: 10.1158/2326-6066.CIR-16-0284. PubMed PMID: 28483787; PMCID: PMC5550830.
Sunay MM, Foote JB, Leatherman JM, Edwards JP, Armstrong TD, Nirschl CJ, Hicks J, Emens LA. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. Int Immunopharmacol. 2017 May;46112-123. doi: 10.1016/j.intimp.2017.02.028. PubMed PMID: 28282575; PMCID: PMC5811992.
Aalipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens LA, Rezaei N. Specific immunotherapy in ovarian cancer: a systematic review. Immunotherapy. 2016 Oct;8(10):1193-204. doi: 10.2217/imt-2016-0034. PubMed PMID: 27605068.
Emens LA, Butterfield LH, Hodi FS Jr, Marincola FM, Kaufman HL. Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer. 2016;442. doi: 10.1186/s40425-016-0146-9. PubMed PMID: 27437105; PMCID: PMC4949883.
Emens LA, Kok M, Ojalvo LS. Targeting the programmed cell death-1 pathway in breast and ovarian cancer. Curr Opin Obstet Gynecol. 2016 Apr;28(2):142-7. doi: 10.1097/GCO.0000000000000257. PubMed PMID: 26881392.
Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016 Mar;29(3):249-58. doi: 10.1038/modpathol.2015.158. PubMed PMID: 26769139; PMCID: PMC5484584.
Cimino-Mathews A, Thompson E, Taube JM, Ye X, Lu Y, Meeker A, Xu H, Sharma R, Lecksell K, Cornish TC, Cuka N, Argani P, Emens LA. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016 Jan;47(1):52-63. doi: 10.1016/j.humpath.2015.09.003. PubMed PMID: 26527522; PMCID: PMC4778421.
Ojalvo LS, Nichols PE, Jelovac D, Emens LA. Emerging immunotherapies in ovarian cancer. Discov Med. 2015 Sep;20(109):97-109. PubMed PMID: 26463091.
Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol. 2015 Aug;42(4):587-600. doi: 10.1053/j.seminoncol.2015.05.013. PubMed PMID: 26320063; PMCID: PMC4555873.
Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology (Williston Park). 2015 May;29(5):375-85. PubMed PMID: 25979549.
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436-43. doi: 10.1158/2326-6066.CIR-15-0064. PubMed PMID: 25941355; PMCID: PMC5012642.
VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P. Reflex estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/Her2) analysis of breast cancers in needle core biopsy specimens dramatically increases health care costs. Am J Surg Pathol. 2015 Jul;39(7):939-47. doi: 10.1097/PAS.0000000000000424. PubMed PMID: 25871620.

<< Investigators Search

Top